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condition can be challenging and expensive. Whilst cellular 
and invertebrate models are frequently used in neurodegen-
erative research and have undoubtedly yielded much use-
ful data, the comparatively simplistic nature of these sys-
tems makes insights gained from such a stand alone model 
limited when it comes to translation. Given the recent 
advances in gene editing technology, the options for novel 
model generation in higher order species have opened up 
new and exciting possibilities for the field. In this review, 
we therefore explain some of the reasons why larger animal 
models often appear to give a more robust recapitulation of 
human neurological disorders and why they may be a criti-
cal stepping stone for effective therapeutic translation.
Why do we need animals to research neurological 
conditions?
The World Health Organisation specifically “pinpoints neu-
rological disorders as one of the greatest threats to public 
health” (http://www.who.int) due in part by an ever-increas-
ing ageing population coupled with an exponential increase 
in the world’s population. There is therefore a critical 
requirement to improve our knowledge of human neuro-
logical disorders which despite their range and prevalence 
are still remarkably poorly understood. One of the major 
limitations for advancing our understanding of these condi-
tions is that the majority of data acquired from patient neu-
rological tissue are obtained at the late or terminal stages 
of disease, where early markers may still be present but are 
nearly impossible to separate from the late-stage chronic 
molecular and/or cellular pathology evident in these sam-
ples. In order to elucidate the molecular cascades result-
ing from the neurodegeneration inducing insult in ques-
tion, and how they alter throughout disease progression, 
Abstract The world health organisation has declared 
neurological disorders as one of the greatest public health 
risks in the world today. Yet, despite this growing concern, 
the mechanisms underpinning many of these conditions 
are still poorly understood. This may in part be due to the 
seemingly diverse nature of the initiating insults ranging 
from genetic (such as the Ataxia’s and Lysosomal storage 
disorders) through to protein misfolding and aggregation 
(i.e. Prions), and those of a predominantly unknown aeti-
ology (i.e. Alzheimer’s and Parkinson’s disease). However, 
efforts to elucidate mechanistic regulation are also likely 
to be hampered because of the complexity of the human 
nervous system, the apparent selective regional vulner-
ability and differential degenerative progression. The key 
to elucidating these aetiologies is determining the regional 
molecular cascades, which are occurring from the early 
through to terminal stages of disease progression. Whilst 
much molecular data have been captured at the end stage 
of disease from post-mortem analysis in humans, the very 
early stages of disease are often conspicuously asympto-
matic, and even if they were not, repeated sampling from 
multiple brain regions of “affected” patients and “con-
trols” is neither ethical nor possible. Model systems there-
fore become fundamental for elucidating the mechanisms 
governing these complex neurodegenerative conditions. 
However, finding a model that precisely mimics the human 
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we must examine repeated samples from model systems 
which are (at least) physiologically representative of three 
key factors: Firstly, the complexity of the human nervous 
system; second, the apparent selective regional vulnerabil-
ity; and third, the differential degenerative progression seen 
in human neurodegeneration. Currently, we cannot achieve 
these solely by the use of in silico or in vitro studies. There 
is therefore an urgent demand for reliable animal models 
that fully mimic neurological disease from genotype to 
phenotype to regional pathophysiology.
The use of animals for scientific research is an emotive 
and often a controversial issue. Nonetheless, without ani-
mal research, it is likely that the mechanisms underpinning 
complex neurodegenerative conditions may never be fully 
understood, new interventions could not be designed and 
drug therapies could not safely be tested. The justification 
for using animals in scientific research is widely accepted 
as a means for improvement of human health either by 
using models to study diseases or for testing the efficacy of 
drugs or vaccines (Greek and Menache 2013). What is not 
widely publicised is the very low rate of translation from 
drug trial through to successful therapy, with those for neu-
rodegenerative research falling far below the average across 
the biomedical sciences (Stanzione and Tropepi 2011; 
Garner 2014). There is certainly room for improvement as 
the translational statistics (highlighted in detail in Garner 
2014) make uninspiring reading for funding bodies and 
drug discovery companies. Such poor translational figures 
also give rise to ethical concerns regarding the effective use 
of animals. To boost both preclinical (animal studies) and 
clinical (human trials) efficacy at the simplest level, experi-
ments need to have stronger hypotheses (or basis in existing 
data), be better designed in methodology/technique, be car-
ried out with a much higher degree of accuracy/reproduci-
bility leading to a higher predictive value and reduced attri-
tion (Greek and Menache 2013; Garner 2014). Therefore, 
an outstanding question remains: what is the best way to 
make animal studies more accurately translate human neu-
rological conditions?
Animal models of human diseases
Model selection is not simple. The criteria for selecting the 
most appropriate model are complex and broad, ranging 
from; does this condition already naturally exist in another 
mammalian system, can a transgenic model be engineered 
to recapitulate the disease in its entirety, and of course, 
financial constraints in carrying out pathological time 
course experiments (see Fig. 1). Funding is extremely com-
petitive and difficult to secure with supporters of biomedi-
cal research increasingly focusing on obtaining deliverable 
targets that are not only reproducible but also translate to 
direct therapeutic intervention (Bowen and Casadevall 
2015). Models then need to be carefully selected in terms 
of “validity” and “yield” as well as potential for knowledge 
advancement.
A technique termed reverse translation could be used 
in the first instance where specific biological markers 
with significant clinical consequences are first determined 
in humans and then applied to an animal model to see if 
they exist and that they reflect the same disease status as 
the human condition (Garner 2014). Thereafter, novel bio-
markers can be identified at different stages of disease in 
the animal model and ideally they would harbour drugga-
ble targets that could delay or even halt the pathological 
disease process altogether (Garner 2014). For example, 
the identification and application of biomarkers in human 
psychiatric conditions which were developed in part using 
a combination of rodent and non-human primate models 
have aided the classification of distinct sub-categories of 
psychoses. These are unbiased and are arguably better diag-
nostic indicators than purely symptomatic-based analysis 
(Keifer and Summers 2016).
Reverse translation methods are not always feasible and 
instead more traditional translational studies are carried out 
in animal models prior to testing in humans. Biomarkers 
are still very relevant in these studies, but it is crucial to 
first understand the mechanistic cascades during the initiat-
ing stages of the disease. Thereafter, biomarker identifica-
tion can occur which may lead to early diagnosis and deter-
mination of disease status, as well as strategies for possible 
therapeutic intervention (Wishart et  al. 2012, 2014; Mut-
saers et al. 2013).
Disorders that occur naturally in both humans and other 
animals with similar aetiology have clear benefits. How-
ever, it is noteworthy that the predictive validity of any 
given animal model of neurodegenerative disease will 
always be impacted upon by physiological and psycho-
logical differences that occur between humans and animals 
(Greek and Menache 2013). Such spontaneous models 
allow researchers to study degenerative processes and to 
elucidate and characterise perturbations occurring early in 
the disease process before symptomatic onset in vivo. This 
is near impossible to do in human patients. Rodents are the 
most commonly used mammalian model for generating 
data from a “large” cohort. They have a relatively short life 
span, rapid breeding cycles, proven transgenic techniques 
available (although technolgies such as CRISPR have par-
tially side-lined this as an advantage) and limited space 
requirements for housing, all of which make them relatively 
inexpensive to fund and thus an attractive option.
Yet, whilst there are many properties of the rodent mod-
els that are advantageous, there are several shortfalls when 
comparing a rodent to a human including but not limited 
to size, anatomy and immunological response to infection 
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(Lorenzen et al. 2015; Whitelaw et al. 2016). Furthermore, 
the relevance of rodent use with regard to certain key fea-
tures of neurological disorders such as motor impairment 
and decision making is also questionable due to differences 
in neuronal network development/maintenance/complexity, 
reduced white matter content, volume and neuronal density 
of key targeted regions such as the substantia nigra or com-
plete absence of brain regions containing gyrencephalic 
cortex, separate caudate and putamen or subthalamic nuclei 
(Morton and Avanzo 2011; Grow et al. 2016). Such large 
disparities generally lead to an incomplete recapitulation of 
a human disorder (see Table  1—detailing the phenotypes 
of some of the current available models with column eight 
and nine representing human pathologies which are not 
recapitulated; Saito et  al. (2014), Zahs and Ashe (2015), 
Philips and Rothstein (2015), Barlow et  al. (1996), Jack-
son et  al. (2013), Wang et  al. (2016), Bible et  al. (2004), 
Pontikis et al. (2005), Morton et al. (2013), Dawson et al. 
(2010), Embourg et  al. (2007), Yang et  al. (2016) and 
Duque et  al. (2015)). It is therefore reasonable to assume 
that basic biological differences between human and rodent 
brains may for some cohorts limit our ability to replicate 
neurodegeneration as observed in patients, especially if 
those traits are polygenetic in nature (Chang et  al. 2015). 
It is also likely that the evolutionary process may also con-
tribute to interspecies differences observed between mod-
els. For instance, it would be reasonable to assume there 
would be a more robust recapitulation of the human disor-
der in models with a higher degree of genetic homology to 
humans. Although Keifer and Summers (2016) argue that 
core molecular mechanisms may be maintained and share 
common features throughout vertebrates, is this enough to 
discover genetic anomalies that are likely to cause subtle or 
even key differences in the disease process? The fact that 
rodents have only 48–66% genetic homology with humans, 
whereas swine and “new world” monkeys have approxi-
mately 80% and “old world” monkeys such as the baboon 
have up to 99%, does beg the question which model is best 
to fully mimic the condition (Grow et al. 2016; Keifer and 
Summers 2016). We would therefore propose that neurode-
generative studies in rodents (outside of conditions caused 
by conserved monogenetic alterations) should be confined 
Fig. 1  This workflow gives an indication of the many considerations 
which should be accounted for when selecting the most appropriate 
animal in which to model a particular disease. The top priority should 
be to select a model that recapitulates the condition in its entirety; 
however, these are rare and often the price of carrying out such 
experiments can be prohibitive. The green arrows indicate the posi-
tive decisions and possible outcomes, with the red arrows represent-
ing a pathway which has been rejected and the blue arrows indicating 
alterative models
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to addressing specific questions relating to aspects where 
the underlying biology is still relevant such as analysis of 
specific substructures or molecular cascades: For exam-
ple, analysis of the degenerating spinal cord (Hunter et al. 
2016) or beta-catenin and WNT signalling cascades in neu-
rons (Wishart et al. 2014), respectively. Moreover, extrap-
olation of results from “lower order” mammals should 
also be limited without adequate evidence of interspecies 
conservation.
There is therefore a requirement for “more biologically 
relevant” larger animal models to either bridge small model 
research with experimental therapeutic trials, or to bypass 
rodent models that do not readily translate the disease in its 
entirety.
Naturally occurring neurological disorders 
observed in humans and large animals
When trying to model progressive neurological condi-
tions of humans, the once ideal short life cycle of rodents 
becomes problematic and inbred models cannot truly 
mimic the diversity of any human population. In contrast, 
ovine and porcine models become an appealing alterna-
tive as they are relatively outbred and are perhaps a more 
socially acceptable species to use in research compared 
to close companion animals such as dogs or cats (Pin-
napureddy et  al. 2015). Interestingly, some disorders 
already naturally exist in these animals.
Neuronal ceroid lipofuscinosis
NCLs, commonly known as Batten disease, are a collec-
tion of rare lethal inherited neuropathological diseases in 
children caused by mutations in genes associated with lyso-
some form and function. Currently, 14 mutations have been 
discovered and each gives rise to subtly different forms of 
the disorder, all of which share the majority of pathological 
and clinical profiles but differing in age of phenotypic onset 
and duration (Geraets et al. 2016). Shared phenotypic traits 
include blindness, cognitive and motor impairment, and 
seizures, and all invariably lead to a greatly reduced lifes-
pan (Geraets et al. 2016).
Several notable discoveries have been determined in a 
naturally occurring ovine model of Batten disease, includ-
ing establishing the nature of the so-called “lipofuscin-
like” storage material and associating neuroinflammation 
with regional cortical atrophy (Pinnapureddy et  al. 2015). 
The ovine model closely mimics the human disorder; there-
fore, any potential molecular targets and therapeutic strat-
egies determined in the sheep could be beneficial across 
multiple genetic variants in humans (Weber and Pearce 
2013; Palmer et al. 2015). Interestingly, a recent study by 
Amorim et  al. (2015) found that many molecular altera-
tions associated with neurodegeneration identified in dros-
ophila and mice models were also conserved in “vulner-
able” synaptic compartments in the brain of CLN5 sheep. 
Such studies reinforce the idea that combined experiments 
across multiple species, building and refining as we pro-
gress, may make for more robust studies for drug targets 
and subsequent therapies.
Currently, combined lentiviral and Adeno-associated 
viral (AAV) vector gene therapies have shown some suc-
cess in the ovine model, and although they are in their 
infancy, the Batten disease phenotype with combined ther-
apy has not yet been studied (and reported on) at an age 
when end-stage disease normally occurs (Palmer et  al. 
2015). So, whilst a “cure” is still a long way off, the utilisa-
tion of such large animal models has informed many factors 
such as gene dosage, delivery routes and viral spread which 
are extremely important for human therapeutics.
Prion disease
Scrapie, a naturally occurring disease in sheep, is a proto-
type for Creutzfeldt–Jakob disease (CJD) in humans with 
many phenotypic similarities including ataxia, depression 
and anorexia and sharing typical pathological hallmarks 
including vacuolation, accumulation of the misfolded pro-
tease-resistant form of prion protein as well as neuronal 
loss (Foster and Hunter 1998). Due to the ability of scrapie 
to breach the species barrier, researchers have successfully 
transmitted several strains to more manageable and less 
financially constraining in-bred mouse models. These mod-
els have been used to characterise and elucidate molecular 
and pathogenic mechanisms that help govern progression 
of the disease, yet they also have their limitations (Siso 
et al. 2012).
The ovine model has been instrumental in determining 
the iatrogenic transmissibility of the disease using blood 
transfusion studies that would not have been physically 
possible to carry out in a rodent model. Multiple sam-
pling throughout the time course of this large mammalian 
model leads to the significant discovery and verification of 
the theory that not only was whole blood infectious during 
various stages of the disease but also that various blood 
fractions harboured infectivity (Yap et  al. 1998; Hunter 
et al. 2002; Houston et al. 2008). The use of large animals 
in this context for these vital studies thereby alerted public 
health officials to the fact that iatrogenic transmission was 
conceivable when receiving a blood or plasma transfusion 
from a seemingly healthy symptomless donor. In turn, the 
results of this report have dictated legislation and protocols 
regarding blood transfusion donation and surgical proce-
dures in the UK (Checchi et al. 2016).
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Duchenne muscular dystrophy
Duchenne muscular dystrophy (DMD) is caused by a 
mutation in the dystrophin gene with devastating down-
stream effects that include muscle fibre damage and physi-
cal disability and lead to a premature death at around 20 
years of age (Rae and O’Malley 2016). This incurable 
disease affects only male patients giving rise to cognitive 
impairment with patients exhibiting a lower intelligence 
quotient (IQ) as well as memory and verbal deficits (Rae 
and O’Malley 2016). A natural model for DMD occurs in 
canines and has been well documented around 50 years 
prior to the development of the currently used genetically 
engineered mice models. To date, there are approximately 
20 canine breeds documented to suffer from DMD, but only 
a couple of these have been well characterised as experi-
mental models most likely due to them being a companion 
animal (McGreevy et al. 2015). Canine DMD clinical phe-
notype and pathology mimic the human disorder almost 
identically, for example, life expectancy is reduced to 25% 
and there are extensive and progressive fore limb fibrosis in 
both species, whilst in rodent models there is only partial 
recapitulation (McGreevy et al. 2015). Yet despite this, the 
majority of the research uses rodent models and therapies 
are yet to be forthcoming as a result (Fuller et  al. 2016). 
There is therefore clear scope to design improved longer 
term experiments within the DMD field.
Human immunodeficiency virus
There are a range of neurological disorders associated with 
human immunodeficiency virus (HIV), which can present 
with mild clinical signs such as asymptomatic neurocogni-
tive impairment to severe forms of dementia (Elbirt et  al. 
2015). Often children are more susceptible to cognitive 
dysfunctions compared to adults infected with HIV (Carryl 
et al. 2015). Although the incidence of these impairments 
has diminished since the introduction of combined anti-
retroviral therapy, the more mild forms still persist and are 
associated with an increased risk in age-related degenera-
tive disorders of the central nervous system (CNS) (Elbirt 
et al. 2015).
Simian immunodeficiency virus (SIV) in monkeys is 
the prototype for HIV and produces the characteristic 
neuropathological changes observed in humans infected 
with HIV (Peeters and Delaporte 2012). A caveat to using 
SIV-infected monkey models is that only 25% naturally 
produce encephalitis with drawn out and irregular incu-
bation periods proceeding the development of acquired 
immune deficiency syndrome (AIDS) (Beck et  al. 
2015). Although this low proportion of uptake could on 
the one hand be seen as problematic, researchers could 
alternatively benefit from elucidating the mechanisms 
evolved in this natural model to evade transmission of 
the virus (Chahroudi et  al. 2014). However, in order to 
produce and characterise classic lentiviral encephalitis 
in an accelerated manner, monkeys can be infected with 
neurotropic-specific strains of SIV or administered with 
antibodies that deplete certain immune cell subsets (Beck 
et al. 2015). With the establishment of lentiviral-induced 
neurologic SIV, several biomarkers have been detected in 
blood and cerebral spinal fluid of monkeys, which have 
been found to correlate with the human condition (Beck 
et  al. 2015; Dezzutti 2015). A positive biomarker status 
can flag up the greater possibility of a patient develop-
ing neurocognitive disorders and clinicians can then treat 
accordingly, meaning such work has the potential to ben-
efit millions of people worldwide (Elbirt et al. 2015).
Genetically engineered large animal models
The advent of numerous scientific and technological 
advances in the twentieth century has resulted in a land-
mark breakthrough in large animal research, with the suc-
cessful cloning of Dolly the sheep in turn leading to the 
cloning of over 20 different species (Pinnapureddy et al. 
2015). In the past decade, advancements in gene editor 
technology have made the production of genetically engi-
neered large animal models more precise and in some 
cases more “fully” recapitulating human disease (Beraldi 
et  al. 2015; Whitelaw et  al. 2016). Whilst technologies 
such as meganucleases zinc finger nuclease (ZFN), Tran-
scription Activator-Like Effector Nuclease (TALEN), 
Clustered Regularly Interspaced Palindromic Repeats 
(CRISPR) and CRISPR associated 9 (Cas9) nuclease 
are still in their infancy yet have the potential to rapidly 
create large animal disease models of human neurologi-
cal conditions to order [discussed in detail by Whitelaw 
et  al. (2016)]. This provides an unprecedented tool for 
high-quality research and preclinical testing of novel 
therapeutics.
Monogenetic disorders
Monogenetic models of disease are technically easier to 
produce than polygenetic disorders. Yet, despite the sim-
plified genetic underpinnings of such conditions, here we 
will describe two transgenic large animal models—ataxia 
telangiectasia (AT) and Huntington′s disease (HD)—dem-
onstrating that even for simple disease-inducing perturba-
tions, they are more successful at recapitulating the neuro-
logical disorder in terms of phenotype and pathology than 
their transgenic rodent counterparts.
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Ataxia telangiectasia
AT is an inherited multi-systemic disorder caused by muta-
tions in the ATM gene. Patients suffer from motor impair-
ment caused by purkinje cell loss, and secondary immune 
disorders often develop leading to diminished life expec-
tancy of approximately 20–30 years. Beraldi et  al. (2015) 
have produced an excellent large animal model of AT in 
a pig with homologous mutations of the ATM gene using 
somatic cell nuclear transfer (SCNT) technology. These 
AT pigs have not only demonstrated characteristic motor 
impairment but also Purkinje cell loss in the cerebellum, 
which is a hallmark of the human disease that has never 
been observed in the rodent models (Beraldi et al. 2015).
It remains unclear why the cerebellum is the target of 
the ATM gene mutation; however, this model has allowed 
researchers to discover for the first time that Purkinje cell 
numbers are reduced at birth. This novel finding has not 
been observed in human patients, due to the nature of sam-
ple acquisition at the terminal phase of disease, and there-
fore further highlights the need to invest in large animal 
models to try and elucidate the cascades and mechanisms 
being initiated in the early stage of disease.
Huntington′s disease
The cause of Huntington′s disease (HD), an autosomal 
dominant inherited invariably fatal disorder, is an expan-
sion of a stretch of the huntingtin (HTT) protein (Howland 
and Munoz-Sanjuan 2014). Pathological aggregation of the 
mutated HTT protein in striatal, cortical, thalamic and hip-
pocampal neurons as well neuronal cell loss is observed 
over the time course of this disease. Typical phenotypic 
hallmarks of HD include severe cognitive deficits, changes 
in personality as well as hyperkinetic movements of the 
limbs which are all extremely distressing to the patients and 
care givers (Ramaswamy et al. 2007).
There are over 25 transgenic rodent models of HD that 
have been made to date, yet none have accurately mimicked 
the neurodegeneration seen in humans suffering from this 
condition (Pouladi et al. 2013; Chang et al. 2015). The nor-
mal order of production of transgenic models has meant 
large animal models of HD have been produced down-
stream of the rodent models and as a result are still to be 
fully characterised (Howland and Munoz-Sanjuan 2014). 
Although in their infancy, there are early indications that 
non-human primate, ovine and porcine models expressing 
mutant Htt (small N terminal fragment) are more suscepti-
ble to the neurotoxic effects of this expression than rodent 
transgenics causing early postnatal death, usually within 
2–3 days of birth depending on fragment expression (Yang 
et  al. 2010; Li and Li 2012; Chang et  al. 2015). Despite 
their premature death, these models have been found to 
display phenotypic and pathologic features such as dysto-
nia and apoptotic cells in the brain, which have not been 
observed in the smaller animal models (Schook et al. 2015; 
Chang et al. 2015). Although it is still early days, prelimi-
nary results from these transgenic large animal models of 
HD suggest they are more suitable to accurately determine 
the therapeutic effects of drug delivery agents on HD-spe-
cific neurodegeneration.
Polygenetic disorders
Dementia of advancing age is an ever-increasing problem 
in the ageing population with huge social and economic 
costs with Dementia UK estimating an annual financial 
outlay of £26 billion. There is therefore a matter of urgency 
to produce robust models to investigate and understand the 
early mechanisms that lead to the onset of polygenetic dis-
orders such as Alzheimer’s disease (AD) and Parkinson’s 
disease (PD). However, due to their polygenetic nature 
and possible environmental influences, it is extremely dif-
ficult to engineer genetic models that fully translate these 
conditions.
Alzheimer’s disease
Of the many genes associated closely associated with AD, 
APP, PSEN1 and PSEN2 are the focus of many studies 
due to their aberrant processing and clearance in the latter 
stages of AD pathogenesis (Chouraki and Seshadri 2014). 
Many transgenic mouse models have been produced target-
ing a single gene mutation, with varied success, but again 
the short rodent life cycle is problematic for these models 
as age is one of the biggest risk factors for contracting AD 
(Hall et al. 2015). With this in mind, pigs became an attrac-
tive option for modelling AD disease not only due to the 
anatomical benefits but also because the identity between 
human and porcine APP is high, with identical secretase 
cleavage sites and the production of Aβ40 and Aβ42 identi-
cal to that produced by humans (Holm et al. 2016). Mini-
pigs expressing APP695 or PSEN1 have been engineered 
using handmade cloning and SCNT technology, but have 
failed to show any pathological changes 2 and 3 years, 
respectively, after production (Holm et  al. 2016). How-
ever, the lack of pathology and behavioural changes may 
be a direct result of the early time points selected to sac-
rifice these models. Although researchers aim to unravel 
pathological events occurring in the preclinical phase 
of disease, both of these models were euthanised within 
the first 10% of their lifespan which may be slightly pre-
mature to uncover any modifications as most dementia 
symptoms do not occur usually present until the latter 80% 
of life (van Vliet et  al. 2013; Dolezalova et  al. 2014). In 
contrast, in vitro analysis of radial glial cells from mutant 
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APP minipigs has detected some early deficits including 
increased astrogenesis, altered expression of ribosomal and 
cell cycle genes and increased hyperphosphorylation of 
Tau (Hall et al. 2015). These could serve as potential indi-
cators into the preclinical aetiology of disease and also add 
weight to the theory that the minipigs were examined at too 
early a time point in the incubation period to detect abnor-
malities consistent with AD phenotypes and pathology. 
Evolution would suggest that non-human primates should 
be the most biologically relevant model to study Alzhei-
mer’s disease. There is a high degree of genetic homology 
(99–100%) of Aβ in great apes and old world monkeys and 
there are obvious physiological and anatomical similari-
ties (Heuer et al. 2012). Interestingly, despite such biologi-
cal similarities, there has not been a reported case of AD 
in NHPs (Toledano et  al. 2012). The longevity of NHPs 
has revealed while they do develop senile plaques and mild 
forms of cognitive decline such as loss of recognition mem-
ory, they have not shown the widespread neuronal loss seen 
in AD patients (Heuer et al. 2012). This further implies a 
complex aetiology underpinning AD which is unlikely to 
be accounted for by aberrations in a single protein.
Parkinson’s disease
Age is one of the biggest risk factors for developing Par-
kinson’s disease (PD) and approximately 1 in 500 people 
in the UK will develop this progressive neurological condi-
tion (Parkinson’s UK). This movement and cognitive disor-
der have many pathologic hallmarks including formation of 
intra-neuronal proteinaceous inclusions, Lewy Bodies and 
the loss of dopaminergic neurons in the Substantia Nigra 
pars compacta (Jagmag et al. 2015). While there are multi-
ple mutations associated with PD, i.e. alpha-synucleinopa-
thies, there is no single genetic anomaly proven to give rise 
to PD; instead, there are a range of polygenetic and envi-
ronmental factors associated with the disease. As a result, 
many models target either the genetic or toxic induction 
pathway.
Experimentally induced parkinsonian-like states have 
been observed in non-human primates, ovine, porcine 
and feline models by intravenous delivery of the dopa-
mine toxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine 
(MPTP) (Beale et al. 1989; Frohna et al. 1995; Mikkelsen 
et al. 1999; Yun et al. 2015). MPTP is lipophilic and crosses 
the blood–brain barrier easily. To date, it has been the best 
inducer of Parkinson-like symptomology and pathology in 
animal models, yet its effect is transient in most mammals 
with the exception of non-human primates and the Göttin-
gen minipig (Mikkelsen et al. 1999). However, only the pri-
mate model has shown expression of Lewy bodies in addi-
tion to depletion of dopaminergic neurons in the substantia 
nigra (Mikkelsen et al. 1999; Yun et al. 2015).
As there are no single gene mutations solely attributed 
to PD, the many rodent knock-out/in models of single gene 
edits show variable success at PD recapitulation. There are 
no successful large animal models with single gene edits 
that have produced Parkinsonian phenotypes or pathology 
(Holm et  al. 2016). However, a group in China have pro-
duced a polygenetic porcine “PD model” with triple gene 
mutations using CRISPR/Cas9 technology targeting par-
kin/DJ-1/PINK1 gene loci in pronuclear embryos (Wang 
et al. 2016). The pigs appear clinically normal at 10 months 
of age; nevertheless, similarly to the AD minipigs, this 
would be considered an early point within the incubation 
period. In silico data analysis reported no significant off-
target cleavages using this delivery system; therefore, the 
application of the technology is assumed to have been 
effective and time will determine the clinical phenotype 
(Wang et al. 2016). If triple targeted genetic manipulation 
proves successful, providing comparable data to the human 
condition, this could potentially bypass the need for rodent 
models and be a major step forward in future investigations 
of therapeutics human polygenetic diseases.
Amyotrophic lateral sclerosis
The majority of neurological disorders with human cor-
relation that spontaneously develop are in larger mamma-
lian species; however, a naturally occurring murine model 
of the polygenetic disorder Amyotrophic lateral sclerosis 
(Holm et al. 2016) exists. The Wobbler mouse has a spon-
taneous mutation in the Vps54 gene and exhibits progres-
sive upper and lower motor neuron degeneration, neuronal 
hyperexcitability and neuroinflammation making it highly 
comparable to human ALS (Moser et al. 2013). This model 
has been well characterised in all three phases of the dis-
ease (pre-symptomatic, evolutionary and stabilised) since 
its discovery 60 years ago allowing trials of various com-
pounds including lecithinised superoxide dismutase (Price 
et  al. 1998) (Moser et  al. 2013). Following these experi-
ments, a SOD1 transgenic rodent model of ALS was pro-
duced in the early 1990s and is currently the most com-
monly used experimental model of ALS (Park 2015).
Although there are now known to be 21 genes mutations 
attributed to ALS, the first and most commonly manipu-
lated is still ALS1 or SOD1 which accounts for approxi-
mately 15% of ALS cases (http://www.alsa.org). To further 
the understanding of this highly targeted mutation, Yang 
et  al. have produced a transgenic pig that expresses the 
human SOD1 transgene using the site mutagenesis tech-
nique nearly two decades after the production of the first 
SOD1 transgenic mouse. At the time of publication, the 
oldest pig was only 2 years of age, yet these pigs exhibited 
hind limb motor disorder together with motor neuron death, 
astrogliosis and skeletal muscle atrophy (Yang et al. 2014). 
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Interestingly, this is the only model of ALS to show some 
nuclear inclusions in motor neurons, located in the interme-
diate zone and ventral horn of the spinal cord, which also 
expressed ubiquitin in the nucleus. Considering this is an 
early time point in the study the larger animal model pro-
duces additional information, pathological deficits, which 
are not observed in the rodent model, and therefore more 
closely models the human condition.
Conclusion
In order to better understand disease mechanisms and 
develop more sophisticated therapeutics, animal models of 
human conditions are a necessity. This is particularly rel-
evant when considering the complex nature of neurological 
disorders. We have highlighted many potential limitations 
of using a rodent to model neurological diseases. These 
include but are not limited to evolutionary distance/segre-
gation, anatomical heterogeneity, disparate life spans, strain 
maintenance/inbreeding and physiological anomalies, and 
can limit our ability to extrapolate to human conditions, 
especially when considering disorders of a polygenetic 
nature. Nevertheless, it is important to note that rodent 
models can and do lead to important discoveries when they 
are employed to address specific questions.
Appropriate model selection for any disorder but espe-
cially those of neurological conditions is a complex pro-
cess that cannot be underestimated (see Fig.  1). Figure  1 
illustrates several possible pathways to decision making 
of model selection from scientific to economic considera-
tions. With significantly increased competition for fund-
ing (perhaps due in part to the lack of successful down-
stream therapeutics), we have emphasised the importance 
of this selection process and discussed the need for robust 
methodological protocols to increase predictive validity. 
The quality of data derived from these models when tak-
ing such considerations into account should therefore lead 
to more effective use of animals in neurodegenerative 
research, more physiologically relevant data generation and 
increased likelihood of translation for therapeutic insights.
Many human neurological disorders naturally exist in 
large animals making them a useful tool for investigating 
early/pre-symptomatic events that can be used as biomark-
ers of disease and/or targets for possible therapeutic inter-
ventions. We highlighted the naturally occurring CLN5 
ovine model of Batten disease as an excellent example of 
how a large animal can not only be used in the identifica-
tion of novel disease determinants, but also in the devel-
opment of potential therapeutics. However, spontaneous 
models are relatively limited and there is, and continues 
to be, a requirement for the production of transgenic mod-
els. Until quite recently, construction of transgenic models 
was only realistic in rodents. However, with the advent of 
pioneering genetic engineering through sophisticated tech-
niques such as TALEN and CRISPR technologies, the pro-
duction of large animal transgenic models is now a reality. 
Although such model production is still in it’s infancy, sig-
nificant advances have already been made in the AT field 
with the generation of a porcine model which has already 
yielded novel insights into embryonic deficits not previ-
ously identified.
Ultimately, the key to any successful model of human 
neurological disease is a robust recapitulation of the condi-
tion. Large animal models can often more closely resemble 
human neurological disorders than their rodent counter-
parts in terms of both phenotype and pathology, providing 
an option for bridging the translational gap between rodents 
and humans.
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